Rezultaty - Clara Libbrecht
- Rezultaty 1 - 2 Rezultaty od 2
-
1
The MERTK/FLT3 inhibitor MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemia od Katherine A. Minson, Catherine C. Smith, Deborah DeRyckere, Clara Libbrecht, Alisa B. Lee‐Sherick, Madeline G. Huey, Elisabeth A. Lasater, Gregory D. Kirkpatrick, Michael A. Stashko, Weihe Zhang, Craig T. Jordan, Dmitri Kireev, Xiaodong Wang, Stephen V. Frye, H. Shelton Earp, Neil P. Shah, Douglas K. Graham
Wydane 2016Artigo -
2
Single-cell multiomics reveals increased plasticity, resistant populations, and stem-cell–like blasts in <i>KMT2A</i>-rearranged leukemia od Changya Chen, Wenbao Yu, Fatemeh Alikarami, Qi Qiu, Chia‐Hui Chen, Jennifer Flournoy, Peng Gao, Yasin Uzun, Fang Li, J. W. Davenport, Yuxuan Hu, Qin Zhu, Kai Wang, Clara Libbrecht, Alex Felmeister, Isaiah Rozich, Yangyang Ding, Stephen P. Hunger, Carolyn A. Felix, Hao Wu, Patrick A. Brown, Erin Guest, David M. Barrett, Kathrin M. Bernt, Kai Tan
Wydane 2021Artigo
Narzędzie wyszukiwania:
Podobne hasła
Biology
Cancer research
Genetics
Immunology
Leukemia
Medicine
Myeloid
Myeloid leukemia
Acute leukemia
Bone marrow
Cancer
Environmental health
Fms-Like Tyrosine Kinase 3
Gene
Haematopoiesis
Internal medicine
MERTK
Mutation
Population
Progenitor cell
Receptor
Receptor tyrosine kinase
Stem cell
Tyrosine kinase
Tyrosine-kinase inhibitor